We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.78 | 1.83% | 43.35 | 43.515 | 42.75 | 42.92 | 6,320,406 | 22:41:03 |
From May 2019 to May 2024
By Ed Ballard
GlaxoSmithKline PLC (GSK.LN) has abandoned a plan to sell some of the North American and European brands in its so-called established products portfolio after failing to find a buyer at the right price.
"The company has evaluated all bids received and has concluded, consistent with its key criteria of maximising shareholder value, not to pursue divestment of these products," GSK said on Thursday.
The drugmaker announced that it was looking for a buyer for the products in July, adding that they were expected to deliver sales of GBP1 billion in 2014.
Shares in GSK closed Thursday 29 pence lower at 1,461 pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
